Income Statement (TTM)
Cocrystal Pharma, Inc. Income Statement shows changes in income and expenses over a period of time. Income Statement data includes Sales and Revenue, Gross Profit, Research and Development (R&D), Selling, General and Administrative Expense (SG&A), Operating Income, Income Tax Expense, Interest Expense, Non-Operating Income, Earnings per Share (EPS), and Shares Outstanding.
All numbers are times 1,000,000 except per share units.
|
2020 09-30 |
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
|
|---|---|---|---|---|---|
| Revenue | 2 | 2 | 2 | 1 | 1 |
| Change (%) | 5.67 | -22.89 | -35.67 | -48.95 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 6 | 6 | 6 | 7 | 7 |
| Change (%) | -4.13 | 4.87 | 6.38 | 0.40 | |
| % of Revenue | 330.22 | 299.60 | 407.47 | 673.87 | 1,325.29 |
| Gross Operating Profit | -4 | -4 | -5 | -6 | -6 |
| Change (%) | -8.39 | 18.78 | 20.06 | 9.00 | |
| % of Revenue | -230.22 | -199.60 | -307.47 | -573.87 | -1,225.29 |
| SG&A | 6 | 6 | 6 | 5 | 6 |
| Change (%) | 0.22 | 0.40 | -10.38 | 14.54 | |
| % of Revenue | 291.40 | 276.37 | 359.82 | 501.30 | 1,124.71 |
| R&D | |||||
| Change (%) | |||||
| % of Revenue | |||||
| OpEx | 12 | 12 | 12 | 12 | 12 |
| Change (%) | -2.09 | 2.72 | -1.48 | 6.43 | |
| % of Revenue | 621.62 | 575.97 | 767.29 | 1,175.18 | 2,450.00 |
| Operating Income | -10 | -10 | -10 | -11 | -12 |
| Change (%) | -3.58 | 8.11 | 3.65 | 11.58 | |
| % of Revenue | -521.62 | -475.97 | -667.29 | -1,075.18 | -2,350.00 |
| Interest Expense | -0 | -0 | -0 | -0 | -0 |
| Change (%) | -11.11 | -12.50 | -0.00 | -14.29 | |
| % of Revenue | -0.47 | -0.40 | -0.45 | -0.70 | -1.18 |
| Net Income | -56 | -10 | -10 | -11 | -12 |
| Change (%) | -82.77 | 7.75 | 3.14 | 11.85 | |
| % of Revenue | -2,938.09 | -479.05 | -669.41 | -1,073.27 | -2,351.57 |
Source: Capital IQ
